1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThe VLRVP provides reimbursement vouchers to Virginia caregivers for the cost of temporary, short-term respite care provided to individuals of any age, with a documented disability or medical condition. The program aims to increase access and reduce barriers to respite care.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Virginia caregivers providing temporary, short-term respite care to individuals of any age with a documented disability or medical condition. Confirm the full requirements in the official notice before applying.
The current listing shows up to $595.00 per family. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Virginia Lifespan Respite Voucher Program (VLRVP) is funded by Virginia Department for Aging and Rehabilitative Services (DARS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The AFID Infrastructure Grant program closes October 30, 2026. Awards top out at $50,000, they are reimbursable, and only a political subdivision can apply. The August round put $507,000 into 14 projects at an average of about $36,000.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article